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DissolutionAbstract Famotidine (FM) is a potent H2-receptor antagonist used for the treatment of peptic
ulcer. It has a low and variable bioavailability which is attributed to its low water solubility. In this
study, the dissolution of the drug was enhanced by a preparation of solid dispersion using two
hydrophilic carriers, namely Gelucire 50/13 and Pluronic F-127. The prepared solid dispersions
were characterized by differential scanning calorimetry (DSC), which indicated that there were
no signs of interaction of the drug with the carriers used in the case of solid dispersions containing
higher polymeric contents (1:3 and 1:5). FM solid dispersions in the matrices of Gelucire 50/13 and
Pluronic F-127 (1:3) were used to prepare pellets. The scanning electron microscope (SEM) images
of pellets showed that the pellets have spherical shape and their size depends on the carrier used.
The dissolution of the drug from either solid dispersion or pellets was performed. The dissolution
study depicted that, the presence of the drug in solid dispersion enhanced its dissolution in compar-
ison with the drug itself. Also, the drug release from the manufactured pellets was found to be
improved in the case of solid dispersions (drug:carrier 1:3). A complete drug release occurred after
30 min from pellets containing solid dispersions, while only about 30% of the loaded FM was
released from pellets containing untreated drug after 2 h.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Solid dispersion technique was selected as it was utilized in a
limited number of researches to increase the solubility of famo-
tidine. Solid dispersion (SD) is deﬁned as the dispersion of one
or more active ingredients in inert carriers at solid state pre-
pared by fusion, solvent, or solvent-fusion methods (Chiou
and Riegelman, 1971; Ford and Rubinstein, 1978). It has been
widely used to improve the dissolution rate, solubility and oral
absorption of poorly water-soluble drugs (El-Badry and
Fathy, 2005; El-Badry and Fathy, 2006; Douroumis et al.,
2007; Thybo et al., 2007). In solid dispersions, the particle size
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enhanced; therefore, drug dissolution is improved markedly
(Craig, 2002; Abdul-Fattah and Bhargava, 2002; Sethia and
Squillante, 2004). Gelucire 50/13 and poloxamer 407 are
among the several carriers which have been employed in pre-
paring solid dispersions (Newa et al., 2008; Yassin et al.,
2009). Gelucire is a family of vehicles derived from the mix-
tures of mono-, di- and triglycerides with polyethylene glycol
(PEG) esters of fatty acids. These Gelucires are available with
a range of properties depending on their hydrophilic-lipophilic
balance (HLB) and melting point range (33–65 C) (Sutananta
et al., 1994; Ainaoui and Vergnaud, 1998). They have a wide
variety of applications in pharmaceutical formulations as in
the preparation of fast release and sustained release formula-
tions (Ainaoui et al., 1997; Cavallari et al., 2005). Poloxamer
407 (P407), also known as Lutrol or Pluronic F127, belongs
to the category of non-ionic surface active agent. It is polyoxy-
ethylene–polyoxypropylene–polyoxyethylene block copolymer
(Pluronics). It is used in the formulation of dosage forms ow-
ing to their low toxicity and ability to form a clear solution or
gel in aqueous media (Alexandridis and Hatton, 1995). Pluron-
ic F127 is also useful in the preparation of topical, rectal and
ocular formulations (Dumortier et al., 2006; Chiappetta and
Sosnik, 2007; Zhang et al., 2002; Ricci et al., 2005).
Famotidine (FM) is indicated for active and maintenance
therapy of different types of ulcers and hypersecretory condi-
tions. The mechanism of action, pharmacological effects, site
of action, and clinical uses are the same as for the other H2-
receptor antagonists, but on equimolar bases, it is reported
to be about 7.5 and 20 times more potent than ranitidine
and cimetidine, respectively, in inhibiting gastric acid secre-
tion. However, it is relatively free of side effects despite its high
potency (Burks, 1995; Page et al., 1997; Kadar, 1998). Famo-
tidine reportedly undergoes minimal ﬁrst-pass metabolism and
its oral bioavailability in man has been reported to be low and
variable (ranging from 40% to 50%) due to its poor aqueous
solubility, high polarity, and gastric degradation (Hassan
et al., 1990; Islam and Narurkar, 1993). Since for poorly
water-soluble drugs (like famotidine) the dissolution rate is of-
ten the rate-limiting step for bioavailability, the dissolution
rate is a function of the solubility and the surface area of the
drug. Thus, dissolution rate will increase if the solubility of
the drug is increased, and it will also increase with an increase
in the surface area of the drug.
Multiple-unit dosage forms have several advantages com-
pared with single-unit dosage forms including more stable
plasma proﬁles and little risk of local side effects (Sandberg
et al., 1988). Among the various types of multiple-unit dosage
forms, pellets have attracted more attention due to their un-
ique clinical and technical advantages. Pellets as a drug deliv-
ery system offer therapeutic advantages such as less irritation
of the gastro-intestinal tract and a lowered risk of side effects
due to dose dumping (Bechgaard and Nielsen, 1978). In addi-
tion, pellets disperse freely in the gastrointestinal (GI) tract,
and so, they invariably maximize drug absorption, reduce peak
plasma ﬂuctuation, and minimize potential side effects without
appreciably lowering drug bioavailability (Eskilson, 1985).
The present study aims to improve FM dissolution rate by
the preparation and characterization of FM solid dispersions
in the water soluble matrices of Gelucire 50/13 and Pluronic
F-127. In addition, immediate release pellets containing FM
or FM solid dispersion systems will be formulated so as tostudy the impact of solid dispersions on the in vitro dissolution
rate of the drug from the pellets.
2. Experimental
2.1. Materials
Famotidine (FM) was kindly supplied by Riyadh Pharma
(Riyadh, Saudi Arabia). Gelucire 50/13, having a melting point
of 50 C and HLB value of 13, was provided by Gattefosse (Ce-
dex, France). Pluronic F-127 (Lutrol F127) was provided by
BASF Aktiengesellschaft (Ludwigshafen, Germany). Micro-
crystalline cellulose (AvicelPH101) was purchased fromServa
Feinbiochemica (Heidelberg, Germany). Lactose monohydrate
was purchased from Winlab (Leicestershire, UK). All other
materials and reagents were of analytical grade of purity.
2.2. Preparation of solid dispersion
Solid dispersions at various weight ratios of 1:1, 1:3 and 1:5 of
FAM:carriers were prepared by melting method. FM was
added to the molten carrier. The drug–polymer blend was
heated 10 C above the melting point of each carrier for
5 min with continuous stirring. The system was placed in a
freezer at 20 C for 24 h. The resulting solid mass was
crushed, ground gently with a mortar and pestle and passed
through 500-lm sieve. The samples were kept in a desiccator
until the next experiments.
2.3. Preparation of physical mixture
Physical mixtures (PM) of Famotidine with Gelucire 50/13,
and Pluronic F-127 (at 1:1, 1:3 and 1:5 weight ratios of
FM:drug) were prepared by blending them by mixing using a
spatula followed with sieving (500 lm).
2.4. Differential scanning calorimetry (DSC)
The samples (3–5 mg) were hermetically sealed in aluminum
pans and heated at a constant rate of 10 C/min, over a temper-
ature range of 25–250 C. Thermograms of the samples were ob-
tained using differential scanning calorimetry (DSC-60,
Shimadzu, Japan). Thermal analysis data were recorded using
a TA 50I PC system with Shimadzu software programs. Indium
standardwas used to calibrate theDSC temperature and enthal-
py scale. N2 was used as purging gas at a rate of 30 ml/min.2.5. Wet massing studies using a mixer torque rheometer
The mixer torque rheometer was used in the present study to
determine the binder ratio required for wet massing during
extrusion/spheronization processes for manufacturing pellets.
It consists of a 135-ml capacity stainless steel bowl equipped
with two mixing blades with rotational speed ranging between
20 and 150 rpm (MTR-3, Caleva, Dorset, England). The data
acquisition and analyses were carried out by a personal com-
puter using data acquisition system and software package sup-
plied by the equipment manufacturer.
Powders were mixed in a turbula mixer (type S27, Erweka,
Apparatebau, Germany) and 15 g sample of this dry blend was
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ing ﬂuid was added in multiple additions over seven wet mass-
ing intervals. Each wet massing interval consisted of a one
minute mixing period and a 20-s data logging (collection) per-
iod with the MTR operating at 50 rpm. Mean line torque was
monitored during the granulation process.
2.6. Manufacture of pellets
The composition of FM or FM solid dispersions containing
pellets is:
FM or FM solid dispersion equivalent to 149 5 g
(avicel 7:3 lactose) ad 151 100 g
Distilled water 153 Q.S.Figure 1 DSC curves of FM (A), Gelucire 50/30 (B), FM-
Gelucire (1:3) physical mixture (C), FM-Gelucire (1:1) solid
dispersion (D), FM-Gelucire (1:3) solid dispersion (E) and FM-
Gelucire (1:5) solid dispersion (F).For the preparation of pellets, avicel, lactose and FM, or
solid dispersions containing FM, were mixed in the turbula
mixer at a certain weight and the powder mixture was wetted
with the binder (water). Next, the resulting wet mass was ex-
truded at a speed of 90 rpm with a screen pore size of
1 mmØ (Mini Screw Extruder, Model MSE1014, Caleva, Dor-
set, England) through 1 mm diameter die. Spheronization was
performed in a spheronizer (Model 120, Caleva, Dorset, Eng-
land) with a rotating plate of regular cross-hatch geometry, at
a speed of 700 rpm, for 5 min. Pellets were then dried on a tray
in a hot oven at 50–60 C for 6 h.
2.7. Pellet drug content
FM content of the manufactured pellets was determined spec-
trophotometrically at 285 nm in triplicate. Pellets were crushed
in a porcelain mortar and about 25 mg of the crushed pellets
was dispersed in 20 ml of distilled water under sonication for
5 min. The supernatant was ﬁltered and measured spectropho-
tometrically. The FM content was calculated using a pre-con-
structed calibration curve.
2.8. Morphological analysis
The morphological characteristics of particles were observed
by scanning electron microscopy (SEM). The samples were
sputter-coated with a thin gold palladium layer under an argon
atmosphere using a gold sputter module in a high-vacuum
evaporator. The coated samples were then scanned and photo-
micrographs were taken with an SEM (Jeol, JSM-1600, To-
kyo, Japan).
2.9. Particle size analysis
The size distribution of the manufactured pellets was investi-
gated using laser light diffraction (Mastersizer Mastersizer Sci-
rocco 2000, Malvern Instruments, Grovewood Road, UK).
For a typical experiment, about 300 mg of pellets was fed into
the sample micro feeder. All samples were analyzed ﬁve times
and average results were taken. The sizes below which 10%
(d(0.1)), 50% (d(0.5)) and 90% (d(0.9)) of the pellets were pres-
ent were used to characterize the pellet size distribution. The
mean diameter was taken as the average of d(0.1), d(0.5) and
d(0.9) values.Span value was used to represent size uniformity and dis-
persity of the microspheres. Hence, a small span value indi-
cates a narrow particle size distribution. Span value was
calculated from the following formula (Chen et al., 2004):
Span ¼ ðD90 D10Þ=D502.10. In-vitro release studies
The release measurements were performed using USP dissolu-
tion apparatus 1 (Caleva Ltd., model 85T), at 50 rpm using a
continuous automated monitoring system which consists of
an IBM computer PK8620 series and PU 8605/60 dissolution
test software, Philips VIS/UV/NIR single beam eight cell spec-
trophotometer Model PU 8620, Epson FX 850 printer, Wat-
son–Marlow peristaltic pump and ﬂasks containing 500 mL
of distilled water. The temperature was maintained at
37 ± 0.5 C. An accurately weighed amount of the prepared
formulation was added to each ﬂask. For each formula, release
was run in triplicate and absorbance was recorded automati-
cally at 285 nm. The percentage of drug release was determined
as a function of time.
3. Results and discussion
3.1. Differential scanning calorimetry (DSC) of solid dispersion
Fig. 1 depicted thermograms of FM, Gelucire 50/13 their PM
and SDs. FM displayed a sharp endothermic peak at 162.99 C
corresponding to its melting point (24–25) with heat of fusion
about 552.47 mJ (Table 1). Gelucire 50/13 showed an endo-
thermic peak at 41.55 C due to its melting point. Thermal
traces for physical mixture, PM (1:3) showed a weak peak
appearing at 161.83 C with heat of fusion about 192 mJ.
For FM-Gelucire solid dispersion at 1:1 ratio, it showed a very
weak broad peak shifted to a lower melting point. The peak
appeared at 161.47 C with heat of fusion about 67.33 mJ.
At higher drug to polymer ratios (1:3 and 1:5), thermal proﬁles
of FM in solid dispersions exhibited a single endothermic peak
corresponding to the fusion of the carrier and the peak of the
drug disappeared completely. Fig. 2 demonstrates DSC scan of
Figure 2 DSC curves of FM (A), Pluronic (B), FM-Pluronic
(1:3) physical mixture (C), FM-Pluronic (1:1) solid dispersion (D),
FM-Pluronic (1:3) solid dispersion (E) and FM-Pluronic (1:5)
solid dispersion (F).
Figure 3 Dissolution proﬁle of FM-Gelucire 50/30 solid
dispersions.
Figure 4 Dissolution proﬁle of FM-Pluronic solid dispersions.
Table 1 Endothermic peaks and DH of FM-Gelucire 50/30 and FM-Pluronic solid dispersions (SD) as well as the 1:3 physical
mixtures (PM) compared with the individual components.
System Polymer Drug
Peak C DH (mJ) Peak C DH (mJ)
Drug == == 162.99 552.47
Gelucire 50/13 41.55 580.10 == ==
Drug:Gelucire
PM 1:3 41.63 201.87 161.83 192.35
SD 1:1 45.22 404.89 161.47 67.33
SD 1:3 43.12 543.89 == ==
SD 1:5 45.10 560.5 == ==
Poloxamer 407 55.08 663.87 == ==
Drug:Pluronic
PM 1:3 55.67 618.41 161.7 264.51
SD 1:1 53.8 166.34 154.44 106.56
SD 1:3 55.30 248.06 == ==
SD 1:5 55.03 554.35 == ==
Figure 5 Mean torque for Avicel PH101 and Avicel PH101-
lactose (7:3) mixture using water as a binder.
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case of PM (1:3), the peak of FM was shallow, broad and ap-
peared at 161.72 C with heat of fusion 264.51 mJ, while itbecame very shallow and shifted to 154.44 C with heat of fu-
sion 106.56 mJ. On the other hand, the characteristic peak of
the drug disappeared completely at drug to polymer ratios of
1:3 and 1:5. All PM (1:3) and solid dispersions exhibited endo-
thermic peaks due to the fusion of Gelucire 50/13 and pluronic
Table 2 Volume weighted mean particle size and the d(0.1), d(0.5), d(0.9) and span values of different pellet formulae loaded with FM
(5% w/w as determined by laser diffractometry.
Pellet formula containing Mean (lm) d(0.1) lm d(0.5) lm d(0.9) lm Span value
Untreated FM 1233.16 899.58 1218.65 1580.81 0.56
FM 1:3 Gelucire solid dispersion 1186.70 864.41 1167.86 1545.79 0.58
FM 1:3 Pluronic solid dispersion 1084.21 771.82 1061.14 1419.68 0.61
Figure 6 (A) Scanning electron micrographs of pellets containing untreated FM, (B) pellets containing FM-Pluronic (1:3) solid
dispersion and (C) pellets containing FM-Gelucire (1:3) solid dispersion.
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DSC indicated a decrease in crystallinity of FM when dis-
persed in the carriers’ matrices. This is in agreement with
(El-Badry et al., 2009), who reported that the DSC thermo-
grams showed the signiﬁcant change in the melting peak of
the indomethacin when prepared as SDs using either Gelucire
50/13 or PEG 4000 suggesting the change in crystallinity of the
drug. The same ﬁnding was reported by (El-Badry, 2011), who
reported that the preparation of solid dispersion of meloxicam
using Gelucire 50/13 enhanced the solubility and dissolution of
the drug due to causing the transformation of the drug to
amorphous form.3.2. In vitro dissolution of FM solid dispersions
Fig. 3 shows the in vitro dissolution proﬁles of FM from its
Gelucire 50/13 solid dispersions of different drug to polymer
weight ratios. Untreated FM exhibited a relatively slower dis-
solution rate, in which about 30% were dissolved within the
ﬁrst 5 min. In addition, only 79% of the loaded drug was dis-
solved after 90 min. The dispersion of FM in the matrices of
Gelucire 50/13, however, effectively improved the drug
dissolution rate. The drug showed that 100%, 97% and 95%
were dissolved from FM 1:1 Gelucire, FM 1:3 Gelucire and
FM 1:5 Gelucire solid dispersions, respectively, within the ﬁrst
Figure 7 In vitro release proﬁles of FM from pellets containing
solid dispersions compared to the untreated drug.
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fromFM-Pluronic F-127 solid dispersions in different ratios are
shown inFig. 4. The dispersion of the drug in the Pluronicmatri-
ces caused a pronounced enhancement of FM dissolution rate,
regardless of the drug to polymer weight ratios used. This in-
crease in the dissolution rate of FMmay be attributed to the fact
that the drug in a solid dispersion system may simultaneously
crystallize out in the veryminute crystals embodied inwater-sol-
uble matrices. This causes an increase in the speciﬁc surface area
of the drug leading to an increase in its dissolution rate (Yoshio-
ka et al., 1995; Lynne and Zograﬁ, 1997; Suzuki and Sunada,
1997). Moreover, the rapid dissolution of these water-soluble
matrices is accompanied by rapid dissolution of the embodied
minute drug crystals. Polymer encircling the drug decreases
aggregation and agglomeration of drug particles, which can
readily dissolve the drug and cause water to contact and wet
the drug particles and so increase its dissolution rate.
3.3. Pellets’ wet masses, sizes and shapes
Pellets were prepared from those wet masses that showed the
highest mean torque value. Fig. 5 shows the rheological proﬁles
forAvicel PH 101 alone andwhenmixed 7 parts with 3 parts lac-
tose. It is clearly evident that there is an increase in wet mass tor-
que with an increase in liquid content, reaching to its maximum
value, and then decreasing as larger volumes of binder are used.
The addition of lactose caused a reduction in the mean line tor-
que of avicel from 0.943 to 0.327 Nm. In addition, the binder ra-
tio (amount of water added for the wetmassing) was found to be
noticeably reduced from 1.33 mL/g in the case of avicel alone to
1 mL/g in the presence of lactose. Therefore, the formula of Avi-
cel 7:3 Lactose was selected as pellet base.
The volume weighted mean particle size and the d(0.1),
d(0.5) and d(0.9) values of different pellet formulae loaded with
FM (as determined by laser diffractometry) are listed in Ta-
ble 2. Generally, the produced pellets showed a size range from
1084 to 1233 lm. In addition, pellet formulations containing
FM solid dispersions (especially the formula containing Plu-
ronic solid dispersion) are slightly smaller in size than those
of untreated FM. Also, the smaller span values reported for
all pellet formulations express their spherecity.Scanning electron micrographs of FM pellets are displayed
in Fig. 6. The prepared pellets were rounded and intact in shape,
except those prepared from untreated FM, which were not com-
pletely spherical. All pellet formulations had smooth surfaces
even the formula that was prepared from untreated drug. This
might be due to a certain solubility of FM in the pellet binder li-
quid (water) during extrusion/spheronization processes.
(Mahrous et al., 2010) showed that more hydrophilic poly-
mer when mixed with Avicel, produced a wet mass having the
lowest mean torque value, that, in turn, reﬂects on the easy
extrusion of wet mass resulting in pellets with less rough sur-
faces. Also, (Law and Deasy, 1997) reported that the use of
hydrophilic polymers with Avicel favored more spherical and
smooth pellets.
3.4. In vitro dissolution of FM from pellet formulations
FM:Gelucire 50/13 (1:3) and FM:Pluronic F-127 (1:3) solid
dispersions were selected to be formulated as pellets and com-
pared to the untreated FM in terms of FM dissolution rate.
The in vitro dissolution proﬁle of FM from pellets containing
different formulas is shown in Fig. 7. The in vitro drug release
from the pellet formulations is slightly slower than that from
the powdered solid dispersion during the ﬁrst dissolution per-
iod. This might be attributed to the compactness of the pellets
caused by the extrusion of the formulation in the presence of
the sphere forming agent (avicel) and the binder liquid; water.
Untreated FM showed a very slow in vitro dissolution rate
from the prepared pellets, in which only 29% of the loaded
drug dissolved after 120 min. In contrast, the pellet formula-
tions containing FM:Gelucire 50/13 (1:3) and FM:Pluronic
F-127 (1:3) solid dispersions showed a noticeable enhancement
in the drug dissolution rate, in which about 78% and 94% of
the incorporated FM were released within the ﬁrst 15 min from
pellets containing FM:Gelucire 50/13 (1:3) and FM:Pluronic
F-127 (1:3) solid dispersions, respectively. It is worthy to men-
tion that pellets containing either Gelucire or Pluronic solid
dispersions showed complete burst within 30 min of the disso-
lution period resulting in complete drug release. These results
are in accordance with (Jachowicz et al., 2000), who showed
that the release of ketoprofen from pellets containing solid dis-
persion was greater than from pellets of the drug alone, in
which after 2 h of dissolution, 74.71% of ketoprofen was dis-
solved from pellets containing ternary solid dispersion,
whereas only 20.32% was dissolved from pellets containing
untreated ketoprofen.
The results revealed that pellets containing FM-Pluronic F-127
soliddispersionwere superior to those containingFM-Gelucire 50/
13 solid dispersion in improving the drug dissolution. This ﬁnding
might be attributed to the slightly smaller size of the pellets contain-
ing Pluronic solid dispersion, Table 1. In addition, Pluronic F127
has a higher HLB value of 22 (Barreiro-Iglesias et al., 2003) com-
pared to Gelucire, whose HLB value is 13 (El-Badry and Fathy,
2006). Therefore, the higher hydrophilicity of Pluronic might be
responsible for the enhancement of FM dissolution from its solid
dispersion compared to Gelucire.4. Conclusion
This study showed that the hydrophilic polymers (Gelucire 50/
30 or Pluronic F127) could be utilized as solid dispersion
Formulation of immediate release pellets containing famotidine solid dispersions 155carriers in the formation of FM pellets. The extent of the dis-
solution improvement of the drug using these carriers was
attributed to the difference in hydrophilicity. The higher
hydrophilicity of Pluronic F127 (represented by its higher
HLB value) made it to be better than Gelucire 50/30 in
improving FM dissolution.Acknowledgement
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